BackEpigenomics AG Overview
Epigenomics AG

Epigenomics AG Return on Equity

Valuation check: ECX.F's ROE is -52.43%, below the sector sector average of 11.85%.

Get informed when a big investor buys or sells

+ Follow

ROE

-52.43%

Return on Equity

-52.43%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Epigenomics AG (ECX.F) FAQ

Epigenomics AG (ECX.F) currently reports a ROE of -52.43%. That is below the sector sector average of 11.85%. Use the charts on this page to explore Epigenomics AG's ROE history and peer comparisons.

Epigenomics AG's ROE of -52.43% is lower than the its sector sector average of 11.85%. That is roughly 542.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Epigenomics AG's current -52.43% should be judged against industry norms (sector average: 11.85%) and against ECX.F's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -52.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for Epigenomics AG, and consider following ECX.F for alerts when major investors trade the stock.